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Abstract
Toxoplasmosis, a highly prevalent disease, is mainly diagnosed by
serology. Incidence studies could be feasible in children, but ethical
concerns restrict blood sampling in this group. Saliva contains
small amounts of crevicular fluid IgG. Dot-ELISA and a protein A
IgG capture immunoassay were standardized for anti-Toxoplasma
gondii IgG in paired saliva and serum samples from 20 adult
volunteers. A frequency of toxoplasmosis of 19% (95% CI 12–28)
was found in 100 saliva samples from university graduates using
both assays. Toxoplasmosis immunoassays using saliva IgG are a
promising tool for the investigation of the epidemiology of this
disease in children and other vulnerable groups.
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Toxoplasmosis, a worldwide zoonosis, presents few or no
symptoms in most patients, despite occasional severe
disease [1]. Detection of specific antibodies in blood or
serum is the main tool for diagnosis. Saliva has been used
for monitoring drugs and hormones [2] and also for
diagnosis of viral [3], yeast [4] or parasitic [5–7] infectious
diseases. Saliva contains secretory immunoglobulin A, from
salivary gland plasma cells, but also IgG and IgM exuded in
the gingival crevicular fluid [8]. Saliva is easy and comfortable
to collect for the patient, especially children, and also easy to
process due to the absence of clotting and complement [9]. We
standardized Dot-ELISA and a protein A IgG capture immuno-
assay for use in purified saliva samples, followed by testing 100
university students’ saliva to determine the prevalence of the
infection in this group.
Materials and Methods
Young adult volunteers supplied 20 paired serum and saliva
samples and serology was validated with both commercial
assays and in-house comparative ELISA [6]. After this, saliva
samples from 100 university asymptomatic students (aged 18–
21 years) were tested using both assays. Those students were
unaware of their previous toxoplasmosis serology. All samples
were collected after informed consent, and the Ethics
Committee of the Medical College and the University of S~ao
Paulo (No. 031/11) approved this project. Each volunteer
provided 5–10 mL of saliva after mouth washing. The saliva
was ice chilled and cleared and supernatants were added at a
1:1 volume of chilled ethanol (13°C). After 1 h in an ice bath,
globulins were pelleted and dissolved in one-tenth of the
original volume of pH 7.4 sodium borate buffer.
Immunoassays
Dot-ELISA. Dot-ELISA was prepared as previously described
[2]. Each strip contains 25 lg of soluble Toxoplasma gondii
antigen or Protein A paired dots. Strips were incubated with
serum or saliva samples for 1 h at room temperature under
agitation. After washings, anti-human IgG peroxidase conjugate
was added for 1 h and the reaction was revealed with 3,3 –
diaminobenzidine and H2O2 with digital imaging. At least one
dot must be stained, and if both dots were stained this was
considered a positive IgG detection.
For IgG capture ELISA, recombinant Staphylococcal protein
A was added to the solid phase for capture saliva IgG, followed
by binding of biotinylated tachyzoite saline antigen, which was
quantitated by avidin peroxidase. The reaction was revealed
using two chromogenic peroxidase substrates, such as OPD
and TMB, with appropriate controls in each plate.
Results
Dot-ELISA
Dot-ELISA results demonstrated consistency between
the serum and saliva samples, without false-negative or
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false-positive samples, as shown in Fig. 1(a). We also
performed a double-dot design Dot-ELISA protein A confir-
matory test on the samples, with one dot spot with protein A
for total IgG detection and a T. gondii antigen second spot for
specific IgG detection in order to avoid the absence of IgG in
saliva samples. IgG was detected in all of the saliva samples,
including the negative and positive control samples, as shown
in Fig. 1(b). We tested 100 university student saliva samples in
this assay, and stained spots are shown in Fig. 1(c), which
demonstrate that all of the saliva samples contained IgG, as
shown in the upper SPA-stained dots, and 19 were clearly
positive for IgG and anti-T. gondii antibodies. The data
demonstrated a frequency of 19% (12.1–28.3 95% confidence
interval). These preliminary data were not confirmed by
blood sampling.
Protein A IgG capture ELISA
We performed the protein A IgG capture ELISA using two
peroxidase substrates with different specificities for
anti-T. gondii IgG detection. Data from 100 university student
saliva samples are shown in Fig. 2. As can be seen, all positive
or negative samples exhibited the same reactivity as shown in
Dot-ELISA, with better discrimination using TMB as peroxi-
dase substrate, which is more sensitive for peroxidase
detection.
Discussion
Our preliminary data demonstrated that the Dot-ELISA
immunoassay detected IgG antibodies against T. gondii in the
(a)
(b)
(c)
FIG. 1. Dot-ELISA results for anti-T. gondii
IgG detection in human saliva. (a) Results of
the volunteers’ paired saliva and serum samples
tested in quadruplicate. Dots contain T. gondii
soluble antigen. Upper lanes, 1/200 serum;
lower lane, 19 reconstituted saliva. Arrows
indicate specific IgG-positive samples. (b) Dou-
ble dot design: upper dot was adsorbed with
Staphylococcal IgG-binding protein A and lower
dot was adsorbed with T. gondii soluble antigen
and reacted with 19 reconstituted saliva from
the volunteers used in A. (c) Dot design as
described in B using samples from university
graduation students, as described in the Meth-
ods section. SPA, protein A dots; TGA, T. gondii
soluble antigen dots.
FIG. 2. Protein A IgG capture ELISA assay of 100 samples of human
saliva using T. gondii biotinylated antigen and revealed using OPD or
TMB. Dot-ELISA positive (+) = closed symbols; Dot-ELISA negative ()
= open symbols; TMB (circles) and OPD (squares). The y-axis was
divided at the threshold of the 95% confidence interval cut-off of the
negative samples. The mean and the SEM for each sample are shown.
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saliva with the same efficiency as in the serum in our small
sample, which is the material most commonly used for this
purpose. We found no correlation of the reactivity in saliva
with its protein content or total IgG content, and both assays
were well controlled for avoiding false-negative results for the
absence of IgG. We confirmed the detection efficiency using
samples of saliva obtained from a large number of young adults
at our university, using either Dot-ELISA or a protein A
capture ELISA. We used this population due to their availability
for expanding saliva testing without attempting to detect IgG
avidity or any other acute infection predictor. Our Dot-ELISA
results are similar to those described in previous studies [10],
in which anti-rubella IgG antibodies were detected in saliva,
and the pioneering study in which anti-T. gondii antibodies
were detected in saliva [6,11].
Saliva could be an extremely important antibody source for
specific groups of patients, such as children, who are often
protected from conventional invasive blood collection proce-
dures. Saliva has also demonstrated positive results in groups
of adults in patient adherence studies; it increases the
confidence and perseverance of individuals undergoing treat-
ment because there is no need to use invasive needles during
consultations, which helps avoid absenteeism [12]. Our data
using Protein A as IgG capture molecule give very good results,
The absence or low levels of IgG in the saliva could be
responsible for the low efficiency of a number of Dot-ELISA
assays reported elsewhere, which did not include careful
controls [13]. Many studies support the idea that in older
volunteers, the rate of serological positivity for toxoplasmosis
is greater [14]. Our results demonstrated a 19% frequency of
serological positivity, which is lower than that demonstrated in
other Brazilian studies; for example, a 50% frequency was
observed in teenagers in low-income neighbourhoods in the
same city [6], and a >70% frequency was observed in adults in
the Brazilian Amazon [15]. We attributed the low frequency
observed in our study to the high-income origin of our
volunteers or university students. The Dot-ELISA and protein
A capture ELISA for the detection of IgG anti-T. gondii in saliva
are promising tools because they use a non-invasive method of
collection. In addition, the technique is highly sensitive and
highly specific and can be performed routinely and easily in the
laboratory at a low cost. The assay also demonstrates potential
for the development of epidemiological studies or quick tests
using small amounts of saliva.
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